nebivolol

(redirected from Bystolic)
Also found in: Thesaurus, Medical.
Related to Bystolic: Nebivolol, Crestor
Translations

nebivolol

n nebivolol m
References in periodicals archive ?
The Merck business contributed $687 million, and the sale of Bystolic rights added $455 million.
These settlement agreements are in addition to the previously announced Bystolic patent infringement settlement agreement with Hetero Labs Ltd.
Collectively, our next generation products, Bystolic, Savella, Teflaro, Daliresp and Viibryd had sales of $202 million in the quarter, representing 69% growth in comparison to the comparable prior year quarter.
Since 2008, we have licensed, developed and launched four products - BYSTOLIC, SAVELLA, TEFLARO and DALIRESP - and acquired and launched VIIBRYD.
Gergel also led the organization through the approval and launch of Bystolic for hypertension and Campral for alcohol dependency.
Two of our other promoted products, Bystolic and Savella, also turned in solid performances during the quarter.
He was also instrumental in the successful launches of Bystolic, and the blockbuster anti-depressants, Celexa and Lexapro, for which he was recognized as part of Medical Marketing & Media's 2003 "Brand Team of the Year.
Reflecting the hard work begun years ago to identify, develop and bring to market new products, we launched Bystolic in 2008 and Savella in 2009.
In just four years we have introduced a total of five new products - Bystolic, Savella, Teflaro, Daliresp and Viibryd, three of which launched during this past calendar year.
Noah also coordinated the successful integration of the Forest cardiovascular and metabolism clinical development teams and managed the group through a highly productive period, helping to strengthen a pipeline that ultimately included compounds such as bystolic and azimilide.
Forest will amortize the one-time cash payment over the remaining patent life of Bystolic.
Janssen and Forest received notification from these companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of BYSTOLIC before the expiration of the '040 patent.